A cure that’s well-tolerated?
That’s BREXAFEMME1,2
A cure that’s well-tolerated?
That’s BREXAFEMME1,2


The most common adverse reactions reported were GI side effects, with the majority being mild and transient2
2 out of 545 patients studied in Phase 3 clinical trials discontinued treatment with BREXAFEMME due to dizziness (1 patient) and vomiting (1 patient)1
No QTc interval prolongation at >5 times the concentration of the indicated dose1
BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp1
There is a pregnancy safety study for BREXAFEMME. If BREXAFEMME is inadvertently administered during pregnancy or if pregnancy is detected within 4 days after a patient receives BREXAFEMME, pregnant women exposed to BREXAFEMME and healthcare providers should report pregnancies to SCYNEXIS, Inc., at 1-888-982-SCYX (7299)1
*Includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.1
†Includes dizziness and postural dizziness.1
GI=gastrointestinal.

Prescribe BREXAFEMME
with confidence.
MOST COMMON ADVERSE REACTIONS (INCIDENCE ≥2%)1
BREXAFEMME (N=545) |
PLACEBO (N=275) |
|
---|---|---|
Diarrhea | 16.7% | 3.3% |
Nausea | 11.9% | 4.0% |
Abdominal Pain* | 11.4% | 5.1% |
Dizziness† | 3.3% | 2.5% |
Vomiting | 2.0% | 0.7% |
BREXAFEMME (N=545) |
---|
Diarrhea 16.7% |
Nausea 11.9% |
Abdominal Pain* 11.4% |
Dizziness† 3.3% |
Vomiting 2.2% |
PLACEBO (N=275) |
---|
Diarrhea 3.3% |
Nausea 4.0% |
Abdominal Pain* 5.1% |
Dizziness† 2.5% |
Vomiting 0.7% |